Imarem 100mg and 400mg Film-coated Tablets

Product Name:

Imarem 100mg Film-Coated Tablets

Imarem 400mg Film-Coated Tablets

MAL Number:
Imarem 100mg Film-Coated Tablets MAL20016150AZ
Imarem 400mg Film-Coated Tablets MAL20016151AZ
Indication:

Treatment of

  • Adult and pediatric patients with newly diagnosed chronic myeloid leukemia (CML) as well as for the treatment of adult and pediatric patients with CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
  • Adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα re-arrangement.
  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
  • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V cKit mutation or with c-Kit mutational status unknown.
Active Ingredient:

Imatinib Mesylate

Pack Size:

Imarem 100 mg film-coated tablets: Packs containing 30 and 60 film-coated tablets.
Imarem 400 mg film-coated tablets: Packs containing 30 film-coated tablets.

Therapeutic Category: Protein-tyrosine Kinase Inhibitor